文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

与疾病发病年龄相关的结直肠癌关键基因 KRAS-BRAF-PIK3CA-PTEN-TP53 的 DNA 序列谱。

DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.

机构信息

Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

出版信息

PLoS One. 2010 Nov 12;5(11):e13978. doi: 10.1371/journal.pone.0013978.


DOI:10.1371/journal.pone.0013978
PMID:21103049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2980471/
Abstract

The incidence of colorectal cancer (CRC) increases with age and early onset indicates an increased likelihood for genetic predisposition for this disease. The somatic genetics of tumor development in relation to patient age remains mostly unknown. We have examined the mutation status of five known cancer critical genes in relation to age at diagnosis, and compared the genomic complexity of tumors from young patients without known CRC syndromes with those from elderly patients. Among 181 CRC patients, stratified by microsatellite instability status, DNA sequence changes were identified in KRAS (32%), BRAF (16%), PIK3CA (4%), PTEN (14%) and TP53 (51%). In patients younger than 50 years (n = 45), PIK3CA mutations were not observed and TP53 mutations were more frequent than in the older age groups. The total gene mutation index was lowest in tumors from the youngest patients. In contrast, the genome complexity, assessed as copy number aberrations, was highest in tumors from the youngest patients. A comparable number of tumors from young (<50 years) and old patients (>70 years) was quadruple negative for the four predictive gene markers (KRAS-BRAF-PIK3CA-PTEN); however, 16% of young versus only 1% of the old patients had tumor mutations in PTEN/PIK3CA exclusively. This implies that mutation testing for prediction of EGFR treatment response may be restricted to KRAS and BRAF in elderly (>70 years) patients. Distinct genetic differences found in tumors from young and elderly patients, whom are comparable for known clinical and pathological variables, indicate that young patients have a different genetic risk profile for CRC development than older patients.

摘要

结直肠癌(CRC)的发病率随年龄增长而增加,发病年龄较早提示其遗传易感性增加。与患者年龄相关的肿瘤发生的体细胞遗传学仍大多未知。我们已经研究了五个已知的癌症关键基因的突变状态与诊断时的年龄之间的关系,并将无已知 CRC 综合征的年轻患者与老年患者的肿瘤的基因组复杂性进行了比较。在 181 名 CRC 患者中,根据微卫星不稳定性状态进行分层,在 KRAS(32%)、BRAF(16%)、PIK3CA(4%)、PTEN(14%)和 TP53(51%)中发现了 DNA 序列变化。在年龄小于 50 岁的患者(n = 45)中,未观察到 PIK3CA 突变,而 TP53 突变的频率高于年龄较大的组。最年轻患者的肿瘤总基因突变指数最低。相比之下,最年轻患者的肿瘤基因组复杂性(评估为拷贝数异常)最高。年轻(<50 岁)和老年(>70 岁)患者的肿瘤数量相当,四个预测基因标志物(KRAS-BRAF-PIK3CA-PTEN)均为四重阴性;然而,年轻患者中有 16%的肿瘤仅存在 PTEN/PIK3CA 突变,而老年患者中只有 1%。这意味着预测 EGFR 治疗反应的突变检测可能仅限于老年(>70 岁)患者的 KRAS 和 BRAF。在年龄较大和较小的患者的肿瘤中发现了明显的遗传差异,这些患者在已知的临床和病理变量方面具有可比性,这表明年轻患者的 CRC 发展遗传风险谱与老年患者不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095a/2980471/bd7ceaf43fb3/pone.0013978.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095a/2980471/12d85ef87b53/pone.0013978.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095a/2980471/bd7ceaf43fb3/pone.0013978.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095a/2980471/12d85ef87b53/pone.0013978.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095a/2980471/bd7ceaf43fb3/pone.0013978.g002.jpg

相似文献

[1]
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.

PLoS One. 2010-11-12

[2]
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Acta Oncol. 2014-7

[3]
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

APMIS. 2013-8-29

[4]
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Genet Med. 2013-2-21

[5]
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Int J Clin Exp Pathol. 2014-8-15

[6]
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.

PLoS One. 2012-5-7

[7]
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther. 2012-6-21

[8]
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.

Sci Rep. 2015-2-2

[9]
Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

J Pathol. 2013-2

[10]
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Clin Colorectal Cancer. 2012-1-28

引用本文的文献

[1]
Assessment of MYC Gene and WNT Pathway Alterations in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients Using Integrated Multi-Omics Approaches.

medRxiv. 2025-2-22

[2]
lncRNAs as prognostic markers and therapeutic targets in cuproptosis-mediated cancer.

Clin Exp Med. 2024-9-26

[3]
Distinct Molecular Profiles of Sporadic Early-Onset Colorectal Cancer: A Population-Based Cohort and Systematic Review.

Gastro Hep Adv. 2022-11-8

[4]
Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.

Clin Med Insights Oncol. 2024-5-25

[5]
Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.

Front Immunol. 2024

[6]
, , microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics.

Cancers (Basel). 2023-10-12

[7]
Molecular characteristics of microsatellite stable early-onset colorectal cancer as predictors of prognosis and immunotherapeutic response.

NPJ Precis Oncol. 2023-7-1

[8]
Colorectal cancer in patients of advanced age is associated with increased incidence of p.V600E mutation and mismatch repair deficiency.

Front Oncol. 2023-6-7

[9]
Molecular genetics of early-onset colorectal cancer.

World J Biol Chem. 2023-3-27

[10]
Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer.

Molecules. 2023-1-11

本文引用的文献

[1]
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.

Mol Biol Rep. 2010-6-23

[2]
Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci.

Mol Cancer. 2010-5-6

[3]
Microsatellite instability in colorectal cancer.

Gastroenterology. 2010-6

[4]
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Eur J Cancer. 2010-4-21

[5]
Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.

Proc Natl Acad Sci U S A. 2010-1-20

[6]
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

J Clin Oncol. 2010-1-25

[7]
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.

Neoplasia. 2009-11

[8]
Colorectal cancer in young adults.

Semin Oncol. 2009-10

[9]
When mutants gain new powers: news from the mutant p53 field.

Nat Rev Cancer. 2009-10

[10]
Microsatellite instability and survival in rectal cancer.

Cancer Causes Control. 2009-8-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索